Related Experiment Video
Updated: Jul 8, 2026

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
Published on: July 3, 2015
Impact of the changes in P-glycoprotein activity on domperidone pharmacokinetics in rat plasma
Magdalena Bamburowicz-Klimkowska1, Katarzyna Zywiec, Agata Potentas
1Department of Toxicology, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, PL 02-097 Warszawa, Poland. mjbamburowicz@op.pl
Abstract:
The effect of quinidine (QD) and grapefruit juice (GFJ) extract, P-glycoprotein inhibitors, on the domperidone (DOM) concentration in rat plasma was investigated. DOM, a dopamine D(2)-receptor antagonist is a substrate for P-glycoprotein. DOM(10 mg/kg) was administered orally 2 h after GFJ extract (0.2 ml/kg) or QD (25 mg/kg). DOM concentration in plasma samples was determined by HPLC with fluorescence detection. The GFJ extract and QD administration significantly increased c(max) of DOM by 19% and 36%, respectively, and the AUC(0-0.25) (area under the concentration-time curve from time zero to 15 min) by 29% and 44%, respectively. In addition, QD significantly increased the DOM AUC(0-2) (32%), whereas 19% increase was observed after GFJ extract administration. In conclusion, GFJ and QD significantly influenced DOM rat plasma concentration during the first two hours after DOM administration indicating that interaction takes place during absorption phase.
Related Concept Videos
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
